Comparison of Comorbid Conditions Between Cancer Survivors and Age-Matched Patients Without Cancer

Satyajeet Roy, Shirisha Vallepu, Cristian Barrios, Krystal Hunter, Satyajeet Roy, Shirisha Vallepu, Cristian Barrios, Krystal Hunter

Abstract

Background: Cancer survivors suffer from many comorbid conditions even after the cure of their cancers beyond 5 years. We explored the differences in the association of comorbid conditions between the cancer survivors and patients without cancer.

Methods: Electronic medical records of 280 adult cancer survivors and 280 age-matched patients without cancer in our suburban internal medicine office were reviewed.

Results: Mean age of the cancer survivors was 72.5 ± 13.1 years, and the age of the patients without cancer was 72.5 ± 12.8 years. The number of male cancer survivors was significantly higher than the female cancer survivors (52.5% vs. 47.5%, P < 0.001). There were significantly more Caucasians and other races (majority Asians) in the cancer survivor group compared to the patients without cancer group (81.8% vs. 79.3% and 4.6% vs. 0.4%, respectively, P < 0.05); while there were significantly less African Americans and Hispanics in the cancer survivor group compared to the patients without cancer group (10.0% vs. 12.8% and 3.6% vs. 7.5%, respectively, P < 0.05). Hypertension (64.3%), hyperlipidemia (56.1%), osteoarthritis (34.3%), hypothyroidism (21.8%), diabetes mellitus (21.8%) and coronary artery disease (21.8%) were the most common comorbid conditions observed in the cancer survivors. Osteoarthritis was the only comorbid condition that was significantly less frequently associated with the cancer survivors compared to the patients without cancer (42.9%, P < 0.05). The frequencies of all other comorbid conditions were not significantly different between the two groups. The majority of our group of cancer survivors had one or more types of the top six cancers which include prostate cancer (30.7%), melanoma (13.9%), thyroid cancer (11.4%), colon cancer (11.1%), uterine cancer (11.1%) and urinary bladder cancer (11.1%); while only a few had cancer of the cervix (6.1%) or breast cancer (0.3%). Use of aspirin, statin, vitamin D, multivitamins, metformin and fish oil supplement in the cancer survivors was similar to the patients without cancer.

Conclusions: Hypertension, hyperlipidemia, osteoarthritis, hypothyroidism, diabetes mellitus and coronary artery disease are the most common associated comorbid conditions in the cancer survivors. Osteoarthritis is less frequently seen in the cancer survivors compared to the patients without cancer. The frequencies of other comorbid conditions are not significantly different between the two groups.

Keywords: Cancer survivors; Comorbid medical conditions; Comorbidities in cancer survivors.

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Age distribution of the cancer survivors.
Figure 2
Figure 2
Frequencies of comorbid conditions in cancer survivors and patients without cancer.
Figure 3
Figure 3
Frequencies of types of cancers in cancer survivors.
Figure 4
Figure 4
Frequencies of comorbid conditions in cancer survivors of top six types of cancers.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442.
    1. Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health. Office of cancer survivorship - definitions. Available at: . Accessed September 9, 2018.
    1. Deimling GT, Bowman KF, Wagner LJ. Cancer survivorship and identity among long-term survivors. Cancer Invest. 2007;25(8):758–765. doi: 10.1080/07357900600896323.
    1. Meadows AT, Varricchio C, Crosson K, Harlan L, McCormick P, Nealon E, Smith M. et al. Research issues in cancer survivorship: report of a workshop sponsored by the Office of Cancer Survivorship, National Cancer Institute. Cancer Epidemiol Biomarkers Prev. 1998;7(12):1145–1151.
    1. Khan NF, Rose PW, Evans J. Defining cancer survivorship: a more transparent approach is needed. J Cancer Surviv. 2012;6(1):33–36. doi: 10.1007/s11764-011-0194-6.
    1. Cancer Research UK. 2006. Cancer Stats. Survival-UK. Available at: . Accessed September 9, 2018.
    1. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer. 2000;88(3):653–663. doi: 10.1002/(SICI)1097-0142(20000201)88:3<653::AID-CNCR24>;2-1.
    1. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol. 1999;52(12):1131–1136. doi: 10.1016/S0895-4356(99)00098-0.
    1. Fu MR, Axelrod D, Guth AA, Cleland CM, Ryan CE, Weaver KR, Qiu JM. et al. Comorbidities and quality of life among breast cancer survivors: a prospective study. J Pers Med. 2015;5(3):229–242. doi: 10.3390/jpm5030229.
    1. De Marco MF, Janssen-Heijnen ML, van der Heijden LH, Coebergh JW. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000;36(1):95–99. doi: 10.1016/S0959-8049(99)00221-X.
    1. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 1996;77(5):834–842. doi: 10.1002/(SICI)1097-0142(19960301)77:5<834::AID-CNCR5>;2-E.
    1. Koroukian SM, Murray P, Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol. 2006;24(15):2304–2310. doi: 10.1200/JCO.2005.03.1567.
    1. Land LH, Dalton SO, Jensen MB, Ewertz M. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat. 2012;131(3):1013–1020. doi: 10.1007/s10549-011-1819-1.
    1. Jorgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353–1360. doi: 10.1038/bjc.2012.46.
    1. Gronberg BH, Sundstrom S, Kaasa S, Bremnes RM, Flotten O, Amundsen T, Hjelde HH. et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010;46(12):2225–2234. doi: 10.1016/j.ejca.2010.04.009.
    1. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. doi: 10.2147/CLEP.S47150.
    1. Gurney J, Sarfati D, Stanley J. The impact of patient comorbidity on cancer stage at diagnosis. Br J Cancer. 2015;113(9):1375–1380. doi: 10.1038/bjc.2015.355.
    1. Geraci JM, Escalante CP, Freeman JL, Goodwin JS. Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol. 2005;23(30):7399–7404. doi: 10.1200/JCO.2004.00.9753.
    1. Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol. 2006;24(31):5017–5024. doi: 10.1200/JCO.2006.07.0243.
    1. Shin DW, Nam JH, Kwon YC, Park SY, Bae DS, Park CT, Cho CH. et al. Comorbidity in disease-free survivors of cervical cancer compared with the general female population. Oncology. 2008;74(3-4):207–215. doi: 10.1159/000151368.
    1. Goytia EJ, Lounsbury DW, McCabe MS, Weiss E, Newcomer M, Nelson DJ, Brennessel D. et al. Establishing a general medical outpatient clinic for cancer survivors in a public city hospital setting. J Gen Intern Med. 2009;24(Suppl 2):S451–455. doi: 10.1007/s11606-009-1027-4.
    1. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW. et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009;124(5):1213–1219. doi: 10.1002/ijc.24054.
    1. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011;38(3):263–265.
    1. Choi KH, Park SM, Lee K, Kim KH, Park JS, Han SH. Prevalence, awareness, control, and treatment of hypertension and diabetes in korean cancer survivors: a cross-sectional analysis of the fourth and fifth Korea national health and nutrition examination surveys. Asian Pac J Cancer Prev. 2013;14(12):7685–7692. doi: 10.7314/APJCP.2013.14.12.7685.
    1. Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, Hamilton AS. et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7(2):253–261. doi: 10.1007/s11764-013-0267-9.
    1. Enright KA, Krzyzanowska MK. Control of cardiovascular risk factors among adult cancer survivors: a population-based survey. Cancer Causes Control. 2010;21(11):1867–1874. doi: 10.1007/s10552-010-9614-6.
    1. Guy GP Jr, Yabroff KR, Ekwueme DU, Rim SH, Li R, Richardson LC. Economic burden of chronic conditions among survivors of cancer in the United States. J Clin Oncol. 2017;35(18):2053–2061. doi: 10.1200/JCO.2016.71.9716.
    1. Nekhlyudov L, Lacchetti C, Davis NB, Garvey TQ, Goldstein DP, Nunnink JC, Ninfea JIR. et al. Head and neck cancer survivorship care guideline: American society of clinical oncology clinical practice guideline endorsement of the American cancer society guideline. J Clin Oncol. 2017;35(14):1606–1621. doi: 10.1200/JCO.2016.71.8478.
    1. Institute of Medicine (US) Committee on Medicare Coverage of Routine Thyroid Screening; Stone MB, Wallace RB, editors. Medicare coverage of routine screening for thyroid dysfunction. Washington (DC): National Academies Press (US); 2003. 3, Prevalence and Consequences of Thyroid Dysfunction. Available from: . Accessed September 9, 2018.
    1. Chin HB, Jacobson MH, Interrante JD, Mertens AC, Spencer JB, Howards PP. Hypothyroidism after cancer and the ability to meet reproductive goals among a cohort of young adult female cancer survivors. Fertil Steril. 2016;105(1):202–207. e201-202.
    1. Keating NL, Norredam M, Landrum MB, Huskamp HA, Meara E. Physical and mental health status of older long-term cancer survivors. J Am Geriatr Soc. 2005;53(12):2145–2152. doi: 10.1111/j.1532-5415.2005.00507.x.
    1. Stava CJ, Beck ML, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. J Cancer Surviv. 2007;1(2):108–115. doi: 10.1007/s11764-007-0016-z.
    1. Griffiths RI, Danese MD, Gleeson ML, Valderas JM. Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. BMC Cancer. 2012;12:613. doi: 10.1186/1471-2407-12-613.
    1. Sanchez Peralta AM, Oliveras-Lopez MJ, Perez Gonzalez R, Martinez Martinez F, Lopez-Garcia de la Serrana H. Prevalence of diabetes in a cancer population in a Malaga hospital. Nutr Hosp. 2012;27(2):456–462.
    1. Karlin NJ, Dueck AC, Cook CB. Cancer with diabetes: prevalence, metabolic control, and survival in an academic oncology practice. Endocr Pract. 2012;18(6):898–905. doi: 10.4158/EP12128.OR.
    1. Lega IC, Pole JD, Austin PC, Lau C, Nathan PC, Baxter NN. Diabetes risk in childhood cancer survivors: a population-based study. Can J Diabetes. 2018;42(5):533–539. doi: 10.1016/j.jcjd.2018.01.004.
    1. Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, Leisenring WM. et al. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv. 2018;2(14):1756–1764. doi: 10.1182/bloodadvances.2018019117.
    1. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44(7):600–606. doi: 10.1002/pbc.20352.
    1. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–749. doi: 10.1016/S0735-1097(03)00759-9.
    1. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW. et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–375. doi: 10.1093/jnci/djk064.
    1. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. doi: 10.1186/1471-2407-10-337.
    1. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31(6):459–467. doi: 10.2165/00002018-200831060-00002.
    1. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465–477. doi: 10.1038/nrclinonc.2009.94.
    1. Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ. et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013;24(6):1574–1579. doi: 10.1093/annonc/mdt019.
    1. Hampton T. Cancer therapy can be hard on the heart: researchers aim to explain - and avoid—cardiotoxicity. JAMA. 2010;303(11):1019–1020. doi: 10.1001/jama.2010.269.
    1. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL. et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100(19):1368–1379. doi: 10.1093/jnci/djn310.
    1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi: 10.3322/caac.21349.
    1. American Cancer Society. 2017. Breast cancer survival rates. Available at: . Accessed September 9, 2018.
    1. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1629–1637. doi: 10.1158/1055-9965.EPI-11-0246.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere